News Image

Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring

Provided By GlobeNewswire

Last update: Sep 18, 2024

Vivos is poised to disrupt the very significant pediatric obstructive sleep apnea (OSA) market with new FDA clearance and new strategic marketing and distribution model

Read more at globenewswire.com

VIVOS THERAPEUTICS INC

NASDAQ:VVOS (2/21/2025, 8:00:01 PM)

After market: 3.15 +0.03 (+0.96%)

3.12

-0.17 (-5.17%)



Find more stocks in the Stock Screener

Follow ChartMill for more